Nothing Special   »   [go: up one dir, main page]

MA43756B1 - Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine - Google Patents

Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine

Info

Publication number
MA43756B1
MA43756B1 MA43756A MA43756A MA43756B1 MA 43756 B1 MA43756 B1 MA 43756B1 MA 43756 A MA43756 A MA 43756A MA 43756 A MA43756 A MA 43756A MA 43756 B1 MA43756 B1 MA 43756B1
Authority
MA
Morocco
Prior art keywords
nicotin
allosteric
receptor modulators
acetylcholine receptor
disease
Prior art date
Application number
MA43756A
Other languages
English (en)
Other versions
MA43756A (fr
Inventor
John Sanders
Brendan Crowley
Brian Campbell
Joseph Duffy
Thomas Greshock
Deodial Guiadeen
Andrew John Harvey
Belinda Huff
Kenneth Leavitt
Vanessa Rada
William Shipe
Linda Suen
Ian Bell
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA43756A publication Critical patent/MA43756A/fr
Publication of MA43756B1 publication Critical patent/MA43756B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Control Of El Displays (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) qui sont utiles comme modulateurs de l'a7 nachr, des compositions contenant de tels composés, et l'utilisation de tels composés pour prévenir, traiter ou améliorer une maladie, en particulier les troubles du système nerveux central tels que les troubles cognitifs dans la maladie d'alzheimer, la maladie de parkinson et la schizophrénie, ainsi que pour la dyskinésie induite par la l-dopa et l'inflammation.
MA43756A 2016-03-22 2017-03-20 Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine MA43756B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311888P 2016-03-22 2016-03-22
US201662369778P 2016-08-02 2016-08-02
PCT/US2017/023127 WO2017165256A1 (fr) 2016-03-22 2017-03-20 Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine

Publications (2)

Publication Number Publication Date
MA43756A MA43756A (fr) 2021-05-19
MA43756B1 true MA43756B1 (fr) 2021-11-30

Family

ID=58455680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43756A MA43756B1 (fr) 2016-03-22 2017-03-20 Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine

Country Status (40)

Country Link
US (3) US20190337910A1 (fr)
EP (2) EP3978479A1 (fr)
JP (1) JP6526352B2 (fr)
KR (1) KR102203552B1 (fr)
CN (1) CN109153649B (fr)
AR (1) AR107928A1 (fr)
AU (1) AU2017237930B2 (fr)
CA (1) CA3018185C (fr)
CL (1) CL2018002697A1 (fr)
CO (1) CO2018009889A2 (fr)
CR (1) CR20180452A (fr)
CY (1) CY1124828T1 (fr)
DK (1) DK3433234T3 (fr)
DO (1) DOP2018000204A (fr)
EC (1) ECSP18078877A (fr)
ES (1) ES2901197T3 (fr)
GE (1) GEP20207149B (fr)
HR (1) HRP20211960T1 (fr)
HU (1) HUE057460T2 (fr)
IL (1) IL261807A (fr)
JO (1) JOP20170067B1 (fr)
LT (1) LT3433234T (fr)
MA (1) MA43756B1 (fr)
MD (1) MD3433234T2 (fr)
MX (1) MX2018011453A (fr)
MY (1) MY195948A (fr)
NZ (1) NZ747408A (fr)
PE (1) PE20181851A1 (fr)
PH (1) PH12018502028A1 (fr)
PL (1) PL3433234T3 (fr)
PT (1) PT3433234T (fr)
RS (1) RS62704B1 (fr)
SG (1) SG11201808220VA (fr)
SI (1) SI3433234T1 (fr)
SV (1) SV2018005743A (fr)
TN (1) TN2018000322A1 (fr)
TW (1) TWI616438B (fr)
UA (1) UA120571C2 (fr)
WO (1) WO2017165256A1 (fr)
ZA (1) ZA201806141B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743327T3 (es) 2015-04-17 2020-02-18 Dow Agrosciences Llc Moléculas que tienen utilidad pesticida y compuestos intermedios, composiciones y procedimientos relacionados con los mismos
EP3526192B8 (fr) 2016-10-12 2021-12-22 Corteva Agriscience LLC Molécules à usage pesticide et intermédiaires, compositions et procédés associés
JP7041141B2 (ja) * 2016-11-01 2022-03-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
WO2019000238A1 (fr) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 5-(pyridin-3-yl)oxazole du récepteur muscarinique m4 de l'acétylcholine
JP7221944B2 (ja) 2017-09-19 2023-02-14 メルク・シャープ・アンド・ドーム・エルエルシー ニコチン性アセチルコリン受容体のヘテロアリールアロステリックモジュレーター
WO2019212927A1 (fr) 2018-05-01 2019-11-07 Merck Sharp & Dohme Corp. Modulateurs allostériques de spiropipéridine des récepteurs nicotiniques de l'acétylcholine
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) * 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
TW202039420A (zh) * 2018-11-26 2020-11-01 美商富曼西公司 用於防治無脊椎害蟲的間二醯胺化合物
EP3962483A4 (fr) * 2019-05-02 2023-01-25 Merck Sharp & Dohme LLC Modulateurs allostériques de spiropipéridine de récepteurs nicotiniques de l'acétylcholine
EP4054569A4 (fr) * 2019-11-05 2023-10-25 Merck Sharp & Dohme LLC Modulateurs allostériques de spiropipéridine de récepteurs nicotiniques de l'acétylcholine
CN111233783B (zh) * 2020-03-13 2021-11-16 温州大学 异噻唑-4-基二硫化物衍生物的合成方法
EP4404934A1 (fr) * 2021-09-21 2024-07-31 Merck Sharp & Dohme LLC Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
CA3235444A1 (fr) * 2021-10-12 2023-04-20 Brown University Traitements de glioblastome multiforme

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487154A (en) 1967-04-03 1969-12-30 Smithkline Corp Method of lowering blood pressure
US3522302A (en) 1967-05-16 1970-07-28 Smithkline Corp P-(2-aminocycloalkyl)benzenesulfonamides
FR2508033A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
US5286736A (en) 1990-11-22 1994-02-15 Dr. Karl Thomae Gmbh Pyridyl compounds and pharmaceutical compositions containing these compounds
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
US6369064B1 (en) 1998-02-17 2002-04-09 Astrazeneca Ab Triazolo(4,5-d)pyrimidine compounds
SE9802574D0 (sv) 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2001227122A1 (en) 2000-01-29 2001-08-07 Lg Chem Investment Ltd. Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
FR2810664B1 (fr) * 2000-06-27 2004-12-24 Adir Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002079152A1 (fr) 2001-03-29 2002-10-10 Bristol-Myers Squibb Company Derives de cyclopropylindole utilises en tant qu'inhibiteurs selectifs de recaptage de la serotonine
EP1490043A4 (fr) 2002-03-26 2007-05-30 Merck & Co Inc Amides spirocycliques en tant que modulateurs du recepteur cannabinoide
WO2004063179A1 (fr) 2003-01-06 2004-07-29 Eli Lilly And Company Arylcyclopropylacetamides substitues servant d'activateurs de glucokinase
EP1833804A1 (fr) * 2004-12-28 2007-09-19 AstraZeneca AB Modulateurs de type arylsulfonamide
JP2009506063A (ja) * 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ，インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法
EP2286807A3 (fr) 2005-09-09 2012-08-29 Kemphys Ltd. Médicament pour le traitement préventif et/ou thérapeutique de l'adhésion de l'intestin
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
KR20100102668A (ko) 2007-12-19 2010-09-24 암젠 인크 염증 조절제로서의 페닐 아세트산 유도체
WO2009086303A2 (fr) 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
AU2009281243A1 (en) 2008-08-12 2010-02-18 F. Hoffmann-La Roche Ag Salicylamide derivatives as nicotinic alpha 7 modulators
JP2012512834A (ja) 2008-12-19 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症、喘息及びｃｏｐｄの処置のためのｃｃｒ２受容体アンタゴニストとしての環状ピリミジン−４−カルボキサミド
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN102333772B (zh) 2009-06-11 2013-12-11 雅培制药有限公司 抗病毒化合物
WO2010144959A1 (fr) 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues d'agents antifibrotiques
WO2011019538A1 (fr) * 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement
WO2012012410A2 (fr) 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Agonistes des récepteurs opioïdes kappa
US20120108500A1 (en) 2010-10-07 2012-05-03 Naoki Sakane Compositions and Methods for Modulating Immunodeficiency Virus Transcription
WO2012083170A1 (fr) 2010-12-16 2012-06-21 Abbott Laboratories Composés antiviraux
KR101925971B1 (ko) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
WO2012103583A1 (fr) 2011-02-02 2012-08-09 Bionomics Limited Modulateurs allostériques positifs du récepteur nicotinique à l'acétylcholine α-7 et leurs utilisations
PL2678327T3 (pl) * 2011-02-23 2017-02-28 Lupin Limited Pochodne heteroarylowe jako modulatory Alfa 7 NACHR
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2013005153A1 (fr) * 2011-07-05 2013-01-10 Lupin Limited Dérivés de biaryle en tant que modulateurs de nachr
UA111746C2 (uk) * 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
WO2013020622A1 (fr) 2011-08-08 2013-02-14 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane-carboxamides en tant qu'antagonistes d'acide lysophosphatidique
WO2014006120A1 (fr) 2012-07-06 2014-01-09 H. Lundbeck A/S Nouveaux modulateurs allostériques positifs de récepteur nicotinique à l'acétylcholine
US20150175534A1 (en) * 2012-08-01 2015-06-25 Merck Sharp & Dohme Corp. Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I
US20150315130A1 (en) 2012-12-10 2015-11-05 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
WO2014172759A1 (fr) 2013-04-24 2014-10-30 Bionomics Limited MODULATEURS DU RÉCEPTEUR NICOTINIQUE α7 DE L'ACÉTYLCHOLINE ET UTILISATIONS DE CEUX-CI - III
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
DK3086815T3 (da) 2013-12-27 2022-05-23 Zymeworks Inc Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater
MX2016008448A (es) 2013-12-27 2017-01-09 Zymeworks Inc Conjugados de var2csa-farmaco.
EP3151833A4 (fr) 2014-06-04 2018-01-10 Thomas Helledays Stiftelse För Medicinsk Forskning Inhibiteurs de mth1 destinés au traitement des états inflammatoires et auto-immuns
AU2015268961B9 (en) 2014-06-04 2019-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
WO2015191799A1 (fr) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Modulateurs de la sous-unité alpha-7 du récepteur nicotinique de l'acétylcholine et leurs utilisations

Also Published As

Publication number Publication date
NZ747408A (en) 2024-07-05
PH12018502028A1 (en) 2019-07-15
TN2018000322A1 (en) 2020-01-16
CA3018185C (fr) 2020-09-15
LT3433234T (lt) 2021-12-10
CR20180452A (es) 2019-02-06
PT3433234T (pt) 2021-12-22
MX2018011453A (es) 2019-01-10
CY1124828T1 (el) 2022-11-25
HRP20211960T1 (hr) 2022-03-18
ZA201806141B (en) 2019-08-28
PE20181851A1 (es) 2018-12-03
SV2018005743A (es) 2019-01-18
AU2017237930B2 (en) 2019-02-07
DOP2018000204A (es) 2019-07-15
US20180030007A1 (en) 2018-02-01
WO2017165256A1 (fr) 2017-09-28
CO2018009889A2 (es) 2018-10-22
KR20180127644A (ko) 2018-11-29
SI3433234T1 (sl) 2022-01-31
MY195948A (en) 2023-02-27
UA120571C2 (uk) 2019-12-26
TW201733989A (zh) 2017-10-01
TWI616438B (zh) 2018-03-01
MD3433234T2 (ro) 2022-02-28
MA43756A (fr) 2021-05-19
ECSP18078877A (es) 2019-02-28
JP2019512508A (ja) 2019-05-16
DK3433234T3 (da) 2022-01-03
AR107928A1 (es) 2018-06-28
SG11201808220VA (en) 2018-10-30
AU2017237930A1 (en) 2018-10-11
CL2018002697A1 (es) 2018-12-28
CN109153649A (zh) 2019-01-04
GEP20207149B (en) 2020-09-10
ES2901197T3 (es) 2022-03-21
KR102203552B1 (ko) 2021-01-18
JP6526352B2 (ja) 2019-06-05
JOP20170067B1 (ar) 2021-08-17
US9840481B2 (en) 2017-12-12
PL3433234T3 (pl) 2022-01-24
CA3018185A1 (fr) 2017-09-28
IL261807A (en) 2018-10-31
US20190337910A1 (en) 2019-11-07
EP3978479A1 (fr) 2022-04-06
CN109153649B (zh) 2022-04-19
EP3433234A1 (fr) 2019-01-30
BR112018069456A2 (pt) 2019-02-05
EP3433234B1 (fr) 2021-10-27
US9926285B2 (en) 2018-03-27
US20170275260A1 (en) 2017-09-28
RS62704B1 (sr) 2022-01-31
HUE057460T2 (hu) 2022-05-28

Similar Documents

Publication Publication Date Title
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA34922B1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
EA202092608A1 (ru) Спиропиперидиновые аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
MA54133A (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
MA32506B1 (fr) Nouveaux composes
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA52375A1 (fr) Inhibiteurs de cdk8/19
MA37748B1 (fr) Composés d'azétidine et de pipéridine utiles comme inhibiteurs de pde10
MA60976B1 (fr) Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine
EA201892113A1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
MA49910B1 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA45392B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA37836A1 (fr) Antagonistes du récepteur 5-ht3